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Abstract
Background: The superior temporal gyrus (STG), which encompasses the primary auditory
cortex, is believed to be a major anatomical substrate for speech, language and communication. The
STG connects to the limbic system (hippocampus and amygdala), the thalamus and neocortical
association areas in the prefrontal cortex, all of which have been implicated in schizophrenia.
Results:  To identify altered mRNA expression in the superior temporal gyrus (STG) in
schizophrenia, oligonucleotide microarrays were used with RNA from postmortem STG tissue
from 7 individuals with schizophrenia and 7 matched non-psychiatric controls. Overall, there was
a trend towards down-regulation in gene expression, and altered expression of genes involved in
neurotransmission, neurodevelopment, and presynaptic function was identified. To confirm altered
expression identified by microarray analysis, the mRNA expression levels of four genes, IPLA2γ,
PIK31R1, Lin-7b and ATBF1, were semi-quantitatively measured using relative real-time PCR. A
number of genes with altered expression in the STG were also shown to have similar changes in
expression as shown in our previous study of peripheral blood lymphocytes in schizophrenia.
Conclusion:  This study has identified altered expression of genes in the STG involved in
neurotransmission and neurodevelopment, and to a lesser extent presynaptic function, which
further support the notion of these functions playing an integral role in the development of
schizophrenia.
Background
The introduction of cDNA microarrays has identified
changes in the expression of hundreds of genes in post-
mortem brain tissue from individuals with schizophrenia
[1-14]. These studies have identified new genes with both
altered expression in, and genetic association to schizo-
phrenia. Many functional groups of genes have been
reported to be altered in these studies including those
involved in neurotransmission, presynaptic functioning,
myelination, neurodevelopment and basic cellular proc-
esses such as cell-cycle regulation and intracellular signal-
ling. The most studied region for gene expression analysis
is the prefrontal cortex (PFC), with fewer comprehensive
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gene expression profiling studies reported for other corti-
cal regions.
The superior temporal gyrus (STG), which encompasses
the primary auditory cortex and is believed to be a major
anatomical substrate for speech, language and communi-
cation [15]. The STG connects to the limbic system (hip-
pocampus and amygdala), the thalamus and neocortical
association areas in the prefrontal cortex, all of which
have been implicated in schizophrenia. Significant evi-
dence suggests the STG plays an important role in the
pathophysiology of some symptoms of schizophrenia.
Structural MRI studies have consistently reported the left
STG volume to be decreased in patients with schizophre-
nia compared to healthy controls [16-20], which was con-
firmed by a recent meta-analysis of 15 voxel-based
morphometry studies [21]. Other studies have reported a
correlation between STG volume and the severity of audi-
tory hallucinations [22,23] and thought disorder [15]. In
addition, the STG is considered to be the generator of mis-
match negativity (MMN), an auditory phenomenon,
which is reduced in individuals with schizophrenia
[24,25].
There are limited reports of post mortem studies of the
cytoarchitecture in the temporal cortex in schizophrenia.
A reduction in the somal volume of deep layer 3 pyrami-
dal cells in the temporal association cortex has been
reported [26], however, [27] and colleagues reported no
alteration of glial density or neuronal size and density in
the Planum Temporale (PT), the posterior portion of the
STG, in schizophrenia. With respect to neurotransmis-
sion, decreased density of muscarinic receptors [28] and
increased density of GABAA  receptors [29] have been
reported in the STG. Despite evidence indicating func-
tional disturbances of the auditory cortex and connections
to most of the brain regions implicated in schizophrenia,
the STG has to date been largely overlooked in large-scale
gene expression, cellular composition and functional
studies in schizophrenia.
In this study, oligonucleotide microarrays were used to
identify altered gene expression in 7 age, gender, PMI and
pH matched pairs of post-mortem STG tissue from indi-
viduals with schizophrenia and healthy controls. To con-
firm altered expression of 4 genes, an additional 6
matched pairs (n = 13) were included in relative real-time
PCR confirmation studies. The expression of two previ-
ously reported putative genes for schizophrenia, RGS4
[30,31] and RIMS2 [14] was also measured. In addition,
the genes found to be significantly altered in the STG were
compared to those previously reported to be altered in
peripheral blood lymphocytes (PBLs) [32]. The findings
of this study suggest that gene expression changes in the
STG may be important in the pathophysiology of this dis-
order.
Results
Altered gene expression in the STG from microarrays
An individual gene was considered to be expressed if flu-
orescence was detected above background levels in at least
4 of the 7 matched pairs. This criterion identified 8737
genes as being expressed in the STG tissue. The average
gene expression for all 19,000 genes across all 7 matched
pairs was calculated and plotted against the level of fluo-
rescence detected (Figure 1). The scatter plot depicts a
slight trend towards overall down-regulation in individu-
als with schizophrenia compared to healthy controls. On
average, the expression of 2448 genes were down-regu-
lated and 946 genes up-regulated, by 1.5 fold or greater in
the STG in schizophrenia compared to controls. To fur-
ther define this list, genes with altered expression greater
than 1.5 fold present in more than 50% (4/7) of the
cohort were selected for further analysis. Using this crite-
ria 191 genes were up-regulated by more than 1.5 fold and
428 were down-regulated by greater than 1.5 fold in the
STG in schizophrenia.
One-class analysis of log 2 transformed expression data
present in at least 4 of the 7 matched pairs was performed
using SAM version 2.0 [33] with 128 permutations. This
limited the list of genes altered by greater than 1.5 fold to
only those genes with significantly altered expression and
as such identified 216 significantly down-regulated genes
and 85 significantly up-regulated genes (Δ = 0.49) with a
false discovery rate (FDR) of 4.7% (Figure 2).
Some of the genes that were significantly altered in the
STG are located within the most reproduced schizophre-
nia linkage loci (Table 2) as were genes with functions
known to be associated with schizophrenia such as neuro-
transmission, myelination and neurodevelopment (Table
3).
Relative real-time PCR confirmation of altered expression
Relative real-time PCR was used to confirm the altered
expression of 4 genes with functional relevance to schizo-
phrenia. Phosphoinositide-3-kinse regulatory subunit
polypeptide 1 (PIK3R1), AT-binding transcription factor 1
(ATBF1), Lin-7 homolog b (Lin-7b) and calcium-inde-
pendent phospholipase A2 gamma (IPLA2γ), had signifi-
cantly altered expression in the STG in schizophrenia
identified by microarray analysis. In addition to the 7
matched pairs used for the microarray analysis, 6 extra
matched pairs were added to enlarge the cohort to 13
matched pairs. Relative real-time PCR analysis confirmed
the microarray data for two of the genes, identifying sig-
nificant up-regulation of ATBF1 (p = 0.01, df = 12, t =
2.56) and IPLA2G (p = 0.04, df = 12, t = 1.94) by 2.39 andBMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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1.53 fold respectively. Although, relative real-time PCR
confirmed the trends in expression from the microarray
analysis with a 1.24 fold up-regulation of PIK31R1 and
1.29 fold down-regulation of Lin7b, these fold changes
were not significant (PIK31R1: p = 0.29, df = 12, t = 0.57;
Lin7b: p = 0.23, df = 12, t = -0.76) (Table 4).
Expression levels of putative schizophrenia genes using 
relative real-time PCR
The expression of a number of putative schizophrenia
candidate genes was analysed using relative real-time PCR
in the STG in the subjects with schizophrenia and com-
pared to controls. RGS4 was present on the microarrays
and displayed a 1.79 fold down-regulation which was sig-
nificant by SAM analysis. The average expression level of
RGS4 mRNA in this cohort measured by relative real-time
PCR was previously reported [31] to be down-regulated
by -2.06 fold (p = 0.03, df = 12, t = -2.33) in the schizo-
phrenia subjects compared to the controls and there was
no significant correlation of altered RGS4 expression and
age (R2 = 0.27, p = 0.18), brain pH (R2 = 0.20, p = 0.32) or
PMI (R2 = 0.15, p = 0.46). The decreased level of expres-
sion of RGS4 mRNA was present in 10 of the 13 matched
pairs [31].
In addition, the RIMS2 mRNA expression level in the STG,
a cytomatrix active zone gene, was investigated since it
had been previously reported to be up-regulated in the
amygdala [14]. Relative real-time PCR analysis of the
mRNA expression levels of RIMS2 was performed and
detected in 12 of the 13 matched pairs using primers and
real-time PCR conditions for RIMS2 as previously
described [14]. The control STG from pair 1 did not
express RIMS2 at a detectable level in both microarray and
real-time PCR analysis and so was excluded. The average
expression level of RIMS2 mRNA detected by relative real-
Average ratio of expression of 19,000 genes in the STG from participants with schizophrenia compared to non-psychiatric con- trols Figure 1
Average ratio of expression of 19,000 genes in the STG from participants with schizophrenia compared to 
non-psychiatric controls. The central blue line indicates an expression ratio of 1 (ie: equal expression) and the two outer 
blue lines indicate a 1.5-fold change. Down-regulation is represented as green, up-regulation as red and normal expression as 
yellow. 191 genes were up-regulated by more than 1.5 fold and 428 were down-regulated by greater than 1.5 fold. The x-axis 
shows the average level of fluorescence present on the microarrays for each gene.BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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time PCR in the 12 matched pairs and normalized to 18s
rRNA, was 1.56 × 10-4 in schizophrenia and 9.09 × 10-5 in
the non-psychiatric controls. The resultant average fold
change in expression of RIMS2 mRNA in the schizophre-
nia subjects compared to the controls was up-regulated by
1.72 fold (p = 0.03, df = 11, t = 2.15) and there was no sig-
nificant correlation of altered RIMS2 expression and age
(R2 = -0.07, p = 0.74), brain pH (R2 = -0.19, p = 0.36) or
PMI (R2 = -0.11, p = 0.61). The up-regulation of RIMS2
mRNA was present in 9 of the 12 matched pairs. Pair 7, 12
and 13 displayed down-regulation of RIMS2 by 1.37, 1.52
and 2.56 fold, respectively. Although, RGS4 and RIMS2
were altered in 10 of 13 pairs and 9 of 12 pairs respec-
tively, the pairs which did not have altered expression of
RGS4 were not the same pairs as those which did not have
altered RIMS2.
Consistent altered expression in PBLs and post-mortem 
STG
The data obtained for gene expression in the STG in schiz-
ophrenia was then compared to gene expression data gen-
erated using microarrays in a previous study of PBLs from
individuals with schizophrenia compared to controls
[32]. None of the cases or controls were the same in each
study. However, three genes were shown to have similar
altered expression in the PBLs and post-mortem STG tis-
sue from individuals with schizophrenia, when compared
to non-psychiatric controls using microarray analysis
(Table 5). Myotubularin-related protein 9 (MTMR9) and
Nuclear Factor κβα (NFκβα) were significantly down-reg-
ulated by SAM analysis in the STG and by greater than 1.5
fold in the PBLs in more than 7 of the matched pairs.
Ewing Sarcoma breakpoint region 1 (EWRS1) was signifi-
cantly up-regulated by SAM analysis in the STG and up-
regulated by greater than 1.5 fold in the PBLs of 8 or more
of the matched pairs.
Discussion
The use of high throughput tools such as microarrays has
broadened the understanding of gene expression altera-
tions in several brain regions in major mental illnesses
such as schizophrenia. These regions include the PFC [1-
4,6,8,12,13,30], cerebellum [9], amygdala [14], hippoc-
ampus [10], as well as the cingulate [13], temporal
[9,11,13], parietal [13], enterohinal [7] and occipital [13]
cortices. Interestingly, the STG, a region reported to be
dysfunctional in schizophrenia has the most pronounced
changes in gene expression when compared to most of the
other regions implicated in schizophrenia [13].
SAM plot of gene expression in the STG from participants with schizophrenia compared to non-psychiatric controls Figure 2
SAM plot of gene expression in the STG from participants with schizophrenia compared to non-psychiatric 
controls. Average expression of 8737 genes expressed in STG tissue from 7 matched pairs of individuals with schizophrenia 
and non-psychiatric controls. The central blue line indicates equal expression and the two outer blue lines indicate significantly 
altered expression (Δ = 0.49, FDR = 0.47), genes in red were significantly up-regulated in schizophrenia compared to controls 
and genes in green were significantly down-regulated in schizophrenia compared to controls. 216 genes were significantly 
down-regulated and 85 genes were significantly up-regulated.BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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The number of genes expressed in the cerebral cortex has
been largely unreported in previous gene expression stud-
ies of the PFC, temporal, parietal and occipital cortices.
Although significantly altered gene expression has been
reported for these areas, identifying the approximate
number of genes expressed, and identifying similar
expression patterns across regions, could lead to further-
ing our understanding of the functional and biological
similarities and differences between cortical areas. In this
study, 8737 of the 19000 genes tested were detectable in
the STG in 4 or more of the 7 matched pairs studied, this
is in contrast to our study of the amygdala, where only
5394 genes were detected using the same 19000 gene
microarray [14]. 4667 genes were expressed in both the
amygdala and STG. Although the STG connects with the
amygdala, the functions of the two regions are quite dis-
tinct which may be reflected in the difference in numbers
of genes expressed. Mirnics and colleagues (2000)
reported an average of 3735 genes expressed in the PFC of
9 individuals with schizophrenia, which is less than half
that for the STG. However the microarray used by Mirnics
and colleagues (2000) contained 7000 gene transcripts
and the criteria to define genes that are expressed different
from this study. Therefore, if tested using a larger gene set
(e.g. 19000) the number of genes expressed in the PFC
may be much higher.
One of the most consistent results across post-mortem
brain studies is a trend towards overall down-regulation
of genes in schizophrenia when compared to healthy con-
trols [4,9,13,14]. The average expression of the gene tran-
scripts measured in this study showed an overall trend
towards down-regulation in the 7 matched pairs of STG
tissue which was similar to that previously reported for
other brain regions in schizophrenia. This global down-
regulation across many brain regions, particularly in the
cerebral cortex including the STG, may contribute to the
generalized deficiencies seen in individuals with schizo-
phrenia, such as poor performance on cognitive tasks,
reduced MMN, pre-pulse inhibition (PPI) and eye-track-
ing dysfunction. Although the biological cause underpin-
ning these deficiencies is yet to be identified, overall
down-regulation of gene expression in many brain 
Table 1: Demographic data for matched pairs consisting of individuals with schizophrenia and non-psychiatric controls.
Pair Gender Age (years) (sz/
cntrl)
Medication 
(CPE) (mg/day)
Duration of 
Illness (years)
Frozen 
Hemisphere
Cause of Death (sz/cntrl) PMI (hours) 
(sz/cntrl)
pH (sz/cntrl)
1 M 51/50 100 24 L ischaemic heart disease/
ischaemic heart disease
21/19 6.02/6.26
2 M 57/58 unknown 26 L cardiac arrhythmia/
ischaemic heart disease
33/38 6.4/6.5
3 M 52/59 450 31 R ischaemic heart disease/
coronary thrombosis
8/20 6.1/6.56
4 M 44/43 500 17 L Suicide/thrombotic 
coronary artery occlusion
35/13 6.55/6.43
5 M 30/34 130–520 3.5 L Suicide/acute exacerbation 
of asthma
24/20.5 6.6/6.73
6 M 32/38 780 13 L Suicide/atherosclerotic 
cardiovascular disease
25/13.5 6.24/6.26
7 M 51/46 300–1300 30 R ischaemic heart disease/
cardiac arrest
18/25 6.62/6.7
8 F 67/70 150–1100 46 R Emphema/ischaemic heart 
disease
27/30 6.2/6.8
9 M 75/73 200–1200 44 L ischaemic heart disease/
respiratory arrest
36/10 6.4/6.2
10 M 54/56 50–600 35 R Coronary artery 
thrombosis/cardiac arrest
27/37 6.2/6.8
11 F 61/56 800–1500 42 R ischaemic heart disease/
pulmonary 
thromboembolus
49/23 6.7/6.7
12 M 67/69 200–2400 41 R ischaemic heart disease/
cardiovascular disease
5/16 6.4/6.6
13 M 57/56 225–975 17 R cardiovascular disease/
Cardiac atheroma
48/24 6.7/6.5
Means SZ 
Control
53.7 ± 13.0
54.5 ± 12.1
*637.9 ± 342.7 28.4 ± 13.2 27.4 ± 13.2
22.2 ± 8.7
6.4 ± 0.2
6.5 ± 0.2
*calculated using the mean CPE dosage for each matched pair.BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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Table 2: Genes in schizophrenia linkage sites with significantly altered expression in the STG in schizophrenia.
SZ Linkage Site GenBank ID Name Symbol Cytoband # pairs changed/7 Average fold change
1q21-q22 NM_006271 S100 calcium binding protein 
A1
S100A1 1q21 5 -1.70
NM_014624 S100 calcium binding protein 
A6 (calcyclin)
S100A6 1q21 4 -2.36
J03651 Mucin 1, transmembrane MUC1 1q21 4 -1.94
AF131738 Hypothetical LOC440675 1q21.1 6 2.05
AJ009640 Sorting nexin family member 
27
SNX27 1q21.3 6 -2.13
AK001560 Immunoglobulin superfamily, 
member 4B
IGSF4B 1q21.2-q22 4 -2.19
NM_014328 RUN and SH3 domain 
containing 1
RUSC1 1q21-q22 5 -3.03
AB040968 Hyperpolarization activated 
cyclic nucleotide-gated 
potassium channel 3
HCN3 1q22 5 1.95
1q32-q42 AK024293 Hypothetical gene AK024293 AK024293 1q32.1 4 1.82
AB037804 KIAA1383 KIAA1383 1q42.2 6 4.09
5q21-q34 NM_014945 Actin binding LIM protein 
family, member 3
ABLIM3 5q32 4 -2.29
AB032364 Early B-cell factor EBF 5q34 5 1.91
6p24-p21 AJ277276 Transcriptional regulating 
factor 1
TRERF1 6p21.1-p12.1 4 -2.38
AB033072 Leucine rich repeat and 
fibronectin type III domain 
containing 2
LRFN2 6p21.2-p21.1 4 -2.38
AB002379 Dishevelled associated 
activator of morphogenesis 2
DAAM2 6p21.2 4 1.69
AF024699 Zinc finger protein 193 ZNF193 6p21.3 6 3.73
NM_014260 HLA class II region expressed 
gene KE2
HKE2 6p21.3 4 -2.18
AK024858 LEM domain containing 2 LEMD2 6p21.31 4 -2.27
AF085841 Proline-rich transmembrane 
protein 1
C6orf31 6p21.32 5 -2.47
AK026291 Ribonuclease P 21 kDa subunit RPP21 6p21.33 5 -2.17
NM_003520 Histone 1, H2bn HIST1H2BN 6p22-p21.3 6 5.01
AK023284 Testis expressed sequence 27 TEX27 6pter-p22.3 7 4.17
6q12-q26 AK026849 Squamous cell carcinoma 
antigen recognized by T cells 2
TSPYL1 6q22-q23 4 -3.79
AK026490 RAB32, member RAS 
oncogene family
RAB32 6q24.3 5 -1.91
8p22-p21 NM_002027 Farnesyltransferase, CAAX 
box, alpha
FNTA 8p22-q11 4 1.72
NM_015458 Myotubularin related protein 9 MTMR9 8p23-p22 4 -2.21
13q13-q32 AF097645 DEAD/H (Asp-Glu-Ala-Asp/
His) box polypeptide 26
DDX26 13q14.12-
q14.2
6 3.49
22q11-q13 AK022886 Activating signal cointegrator 1 
complex subunit 2
ASCC2 22q12.1 5 1.96
NM_000967 Ribosomal protein L3 RPL3 22q13 5 -3.65
NM_002305 Lectin, galactoside-binding, 
soluble, 1 (galectin 1)
LGALS1 22q13.1 4 -3.11
AK025423 Hypothetical protein 
MGC52010
MGC52010 22q13.1 5 -1.67
NM_002676 Phosphomannomutase 1 PMM1 22q13.2 6 -2.52
NM_002490 NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 6
NDUFA6 22q13.2-
q13.31
5- 2 . 8 3
AK026892 Ceramide kinase CERK 22q13.31 5 -1.83BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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Table 3: Genes with significantly altered expression in the STG in schizophrenia according to functional group.
Functional Group GenBank ID Name Symbol Cytoband # pairs changed/7 Average 
Fold Change
Neuro- transmission NM_000834 Glutamate receptor, ionotropic, N-
methyl D-aspartate 2B
GRIN2B 12p12 4 1.98
AL157442 Glutamate receptor, ionotropic, N-
methyl D-asparate-associated 
protein 1 (glutamate binding)
GRINA 8q24.3 6 -2.33
AK024507 Glutamate receptor interacting 
protein 2
GRIP2 3p24-p23 4 -1.73
AB043997 Solute carrier family 5 (choline 
transporter), member 7
SLC5A7 2q12 5 2.07
AF263613 Intracellular membrane-associated 
calcium-independent phospholipase 
A2 gamma*
IPLA2(γ)7 q 3 1 6 1 . 8 8
AF311862 Lin-7 homolog B (C. elegans) LIN7B 19q13.3 6 -3.00
AL137559 Synaptotagmin VII SYT7 11q12-q13.1 4 -1.90
NM_007232 Histamine receptor H3 HRH3 20q13.33 4 -2.00
Presynaptic function AJ132089 Dynein, axonemal, heavy 
polypeptide 10
DNAH10 12q24.31 6 4.08
AB011131 Piccolo* PCLO 7q11.23-q21.3 4 -2.23
Myelination AF179481 Acyl-CoA synthetase bubblegum 
family member 1*
Ascbg1 15q23-q24 5 -1.94
Neuro- development AL050059 Disabled homolog 1 (Drosophila) DAB1 1p32-p31 4 -2.49
NM_006885 AT-binding transcription factor 1 ATBF1 16q22.3-q23.1 6 2.77
NM_006156 Neural precursor cell expressed, 
developmentally down-regulated 8
NEDD8 14q11.2 5 -2.62
AF087991 Netrin G1 NTNG1 1p13.3 5 -2.57
AF009311 Semaphorin 5A SEMA5A 5p15.2 4 2.23
Intracellular signalling M61906 Phosphoinositide-3-kinase, 
regulatory subunit 1 (p85 alpha)
PIK3R1 5q13.1 7 4.10
NM_003632 Contactin associated protein 1 CNTNAP1 17q21 4 -2.74
NM_006078 Calcium channel, voltage-
dependent, gamma subunit 2
CACNG2 22q13.1 4 -2.16
NM_003385 Visinin-like 1 VSNL1 2p24.3 5 -2.15
NM_005031 FXYD domain containing ion 
transport regulator 1 
(phospholemman)*
FXYD1 19q13.1 5 -3.07
Other brain related 
illnesses
NM_005503 Amyloid beta (A4) precursor 
protein-binding, family A, member 
2 (X11-like)
APBA2 15q11-q12 4 -2.55
NM_004860 Fragile × mental retardation, 
autosomal homolog 2
FXR2 17p13.1 5 -2.16
Other functions AB002340 Lupus brain antigen 1 LBA1 3p22.3 4 -1.89
NM_002629 Phosphoglycerate mutase 1 (brain) PGAM1 10q25.3 4 -2.18
NM_016223 Protein kinase C and casein kinase 
substrate in neurons 3
PACSIN3 11p12-p11.12 5 -2.22
NM_005619 Reticulon 2 RTN2 19q13.32 4 -1.72
NM_001048 Somatostatin SST 3q28 5 -3.02
U27768 Regulator of G-protein signalling 4* RGS4 1q23.3 4 -1.79
M96577 E2F transcription factor 1 E2F1 20q11.2 6 -2.59
AK023573 Synapse defective 1, Rho GTPase, 
homolog 1 (C. elegans)
7h3 19p13.12 4 -1.71
X87825 Olfactory receptor, family 7, 
subfamily E, member 47 
pseudogene
OR7E47P 12q13.13 6 7.32
X89668 Olfactory receptor, family 7, 
subfamily E, member 19 
pseudogene
OR7E19P 19p13.2 7 2.23
*Previously reported to be altered in schizophrenia.BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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regions may be the first steps towards explaining these
phenomena.
The number of genes with altered expression in the STG
identified by SAM and a 1.5 fold change cut-off in this
study was remarkably similar to that reported by Katsel
and colleagues (2005) using a high stringency criteria.
This study identified 216 genes down-regulated and 85
genes up-regulated whereas Katsel and colleagues (2005)
reported 185 genes down-regulated and 88 genes up-reg-
ulated in the same region in 22 schizophrenia and control
samples. Although the genes identified in each study
could not be directly compared.
The dysregulation of gene expression observed in the STG
also highlighted a number of key cellular pathways
including neurotransmission, particularly glutamate sign-
aling, neurodevelopment and neuronal differentiation
and presynaptic function. Indeed, there is building evi-
dence for dysfunction of glutamate synapses in the STG
and temporal lobe in general. For example, increased den-
sity of the N-methyl-D-aspartate (NMDA) glutamate
receptor was reported by Nudmamud and colleagues [34]
using ligand binding studies and Le Corre and colleagues
[35] used in situ hybridization to show increased density
of the NMDA NR1 subunit splice variant in the STG from
subjects with schizophrenia. In addition, Eastwood and
Harrison (2001) [36] reported that complexin II mRNA
(expressed in excitatory neurons) was reduced in the dor-
solateral PFC and the superior temporal cortex, and com-
plexin I mRNA (expressed in inhibitory neurons) was
decreased in the superior temporal cortex in schizophre-
nia. Furthermore, several of the schizophrenia candidate
genes (e.g. glutamate receptor, metabotropic 3 (GRM3),
G72, D-amino acid oxidase (DAAO), proline dehydroge-
nase oxidase 1 (PRODH), neuregulin 1 (NRG1) and pro-
tein phosphatase 3 catalytic subunit gamma isoform
(PPP3CC)) are thought to be directly or indirectly linked
with glutamatergic transmission via NMDA receptors
[37,38].
In this current study of the STG, the IPLA2γ gene was sig-
nificantly up-regulated. IPLA2γ is an isoform of IPLA2
expressed in many tissue types, including the brain [39].
IPLA2, a key enzyme for phospholipid degradation, is
vital for the maintenance and formation of cellular mem-
branes [40]. IPLA2 is involved in neurotransmission via
modulation of phosphorylation of the AMPA glutamate
receptors. Endogenous IPLA2 activity limits phosphoryla-
tion on serine sites of the AMPA receptor GluR1 subunit,
resulting in IPLA2 control over AMPA mediated synaptic
transmission in the hippocampus [41,42]. There are,
however, limited reports of IPLA2 function in other brain
regions and the control over AMPA-mediated transmis-
sion is yet to be studied in areas such as the STG. IPLA2 is
thought to be involved in learning and memory via alter-
ations in hippocampal plasticity [43], deficiencies of
which are key indicators of schizophrenia. Contrary to
most reports being related to hippocampal tissue, IPLA2
protein expression has previously been reported to be
increased by up to 45% in post-mortem temporal cortex
[44] and in blood serum of individuals with schizophre-
nia [45,46], thus suggesting IPLA2 is worthy of further
study.
Furthermore, the microarray analysis also showed that
other genes involved in glutamate signaling were altered
in the STG in patients with schizophrenia. These include,
glutamate receptor, ionotropic, N-methyl D-aspartate 2B
(GRIN2B) subunit, also known as NR2B, that had signifi-
cantly up-regulated expression, and two glutamate recep-
tor interacting proteins glutamate receptor N-methyl D-
Table 4: Fold changes in gene expression in the STG from individuals with schizophrenia compared to non-psychiatric controls that 
were identified by microarrays and confirmed by relative real-time PCR.
Microarray results Real-Time PCR results
GenBank ID Symbol Fold Change Pairs Changed/7 Fold Change Pairs changed/13 P Value
NM_006885 ATBF1 2.77 6 2.39 11 0.01
AF263613 IPLA2G 1.88 6 1.53 9 0.04
M61906 PIK31R1 4.1 7 1.24 9 0.29
AF311862 Lin7b -3 6 -1.29 9 0.39
Table 5: Genes with altered expression in post-mortem STG and PBLs from individuals with schizophrenia.
GenBank Acc. Name STG Pairs changed/7 Average STG fold change PBLs Pairs changed/14 Average PBLs fold change
NM_015458 MTMR9 5 -2.2 11 -2.2
NM_020529 NFκβα 6- 2 . 81 0- 1 . 3
NM_005243 EWSR1 4 1.5 7 1.15BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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asparate-associated protein 1 (GRINA) and glutamate
receptor interacting protein 2 (GRIP2) showing signifi-
cant down-regulated expression in schizophrenia sub-
jects. Furthermore, Lin-7b, which was downregulated in
the STG of schizophrenia patients by microarray analysis,
is highly enriched in post-synaptic densities (PSD) in
association with PSD95/NMDA receptor complexes [47].
More specifically, Lin-7b is a PSD-95/Dlg/ZO-1 (PDZ)
domain containing protein, which increases the channel
activity of the NR1-NR2B glutamate receptor [48]. Thus,
the evidence from this study supports dysfunction of
glutamate transmission in the STG in the pathophysiol-
ogy of schizophrenia.
Alteration to neurodevelopment and neuronal differenti-
ation in the STG is supported by the significant up-regula-
tion of ATBF1 by microarray and real-time PCR analysis in
the STG tissue from individuals with schizophrenia com-
pared to the non-psychiatric controls. This gene is highly
expressed in the central nervous system, in particular
dopaminergic neurons during neuronal differentiation
[49]. The expression of ATBF1 results in suppression of
the nestin gene and activation of the Neurogenic differen-
tiation 1 (NEUROD1) gene, which are responsible for
specific neuronal differentiation [50]. NEUROD1 was up-
regulated in a gene expression study of the middle tempo-
ral gyrus (MTG) in schizophrenia [11], which may be a
direct result of ATBF1 up-regulation similar to that
observed in this study. Overexpression of ATBF1 in neu-
roblastoma cell lines produces cell cycle arrest, which is
thought to occur in vivo as the result of nuclear localiza-
tion of ATBF1 in differentiating neurons [50]. Therefore,
overexpression of ATBF1 in the STG of patients with schiz-
ophrenia might reflect deficits in neuronal differentiation
and neurodevelopment
There have been a number of reports indicating dysregu-
lation of presynaptic function genes [51]. Indeed, our pre-
vious study of the amygdala [14] highlighted dysfunction
of the genes coding for proteins in the cytomatrix active
zone, a specialized region of the synapse involved in the
regulation of vesicle release. RIMS2 codes for a protein
that forms part of the cytomatrix of the active zone of syn-
apses and was observed to be upregulated in the amygdala
in schizophrenia [14]. The STG directly connects to the
limbic system, of which the amygdala is a constituent. In
this study RIMS2 was significantly up-regulated by 1.72
fold, similar to the 2.37 fold change reported in the amy-
gdala. In contrast, Mirnics et al (2001a) reported a down-
regulation of presynaptic function genes, although those
genes were not investigated in this study. RIMS2 modu-
lates Ca2+-triggered exocytosis and may be overexpressed
in the STG as a compensatory mechanism to overcome
other presynaptic function deficiencies.
Regulator of G-protein signaling 4 (RGS4) is a schizophre-
nia candidate gene that was identified by Mirnics and col-
leagues [30,51] and has subsequently been reported in
linkage [52] and convergent functional genomics studies
[53]. The relative expression level of RGS4 mRNA in the
STG from the cohort used in this study has been previ-
ously reported as significantly down-regulated by an aver-
age fold change of -1.93 by relative real-time PCR [31],
which was confirmed in the current study as a significant
down-regulation of -1.79 fold by microarray analysis. This
down-regulation of RGS4 expression in the STG is in
accordance with the decreased expression previously
reported in the PFC, motor and visual cortices in schizo-
phrenia [30] further establishing RGS4 as a schizophrenia
candidate gene.
Changes in gene expression in PBLs are emerging as bio-
logical reflections of altered expression in the brain as
described in [32]. Consistent with previous studies [54] 3
genes, MTMR9, EWSR1 and NFκβα were altered in the
same direction in the post-mortem STG tissue and the
peripheral blood lymphocytes (PBLs) from a separate
cohort of individuals with schizophrenia identified in a
previous study [32]. Whether this may lead to the use of
PBLs in the development of a biological basis for identify-
ing individuals with schizophrenia awaits further investi-
gation.
The findings of this study and previous gene expression
studies involving post-mortem brain tissue are limited by
the availability of tissue and the potential of mRNA
expression alterations being due to mRNA degradation
from variables such as brain pH and PMI [55]. To control
for this potential bias in this study, post-mortem brain tis-
sue from individuals with schizophrenia and non-psychi-
atric controls were carefully screened and matched for
brain pH and PMI in addition to brain hemisphere, age
and gender. The tissue pH for pairs 3, 8 and 10 were not
as closely matched as the remaining pairs, however there
was no correlation between lower pH in the patients,
numbers of genes expressed, levels of gene expression on
the microarrays or in the relative levels of gene expression
measured by real-time PCR. Even though all the variables
thought to influence RNA integrity and gene expression
were controlled for as much as possible in this study, one
cannot rule out the possibility that differences in pH
could cause changes in gene expression in post-mortem
brain tissue.
In addition to this, another variable which may influence
post-mortem tissue gene expression is anti-psychotic
medication. The large range of chlorpromazine equiva-
lents (CPE) dosages across the cohort as well as the medi-
cation history of one individual being unknown resulted
in the inability to perform correlation analyses betweenBMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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anti-psychotic medications and altered gene expression,
therefore the influence of anti-psychotic medications on
the genes with altered expression in the STG requires fur-
ther investigation.
Conclusion
This study has shown altered expression via microarrays
and real-time PCR of genes in the STG involved in neuro-
transmission (particularly glutamate transmission), neu-
rodevelopment, and to a lesser extent presynaptic
function. These alterations in gene expression particularly
involving glutamate-related transcripts, are likely to have
dramatic consequences for neurotransmission in the STG
in schizophrenia.
Methods
Characteristics of subjects
This study was approved by the University of Newcastle
Human Research Ethics Committee, Australia. Blocks of
coronally sectioned post-mortem STG tissue (1 cm thick)
were sourced from the NSW Tissue Resource Centre, The
University of Sydney, Australia. Tissue from 13 pairs of
individuals with schizophrenia and controls were
matched for gender, age, brain hemisphere, post-mortem
interval (PMI) and pH (Table 1). Differences in the age,
PMI and pH of the schizophrenia and control groups were
not statistically significant (paired 2 tailed t-test). Pairs 1–
7 were used for microarray analysis, whilst all 13 pairs
were used for the relative real-time PCR studies. These
cases were the same cohort used in a previous study of
RGS4 expression [31].
RNA extraction
RNA was extracted as described in [31]. Briefly, a hole
punch of grey matter, excluding white matter, was taken
from the outer edge of the block of STG from the most
caudal coronal brain slice (1 cm thick) containing the STG
(Brodmann's Area 22). Total RNA was extracted using TRI-
zol reagent (Gibco-BRL, USA) as described previously
[14]. Briefly, approximately 50–60 mg tissue was added to
1 ml TRIzol reagent and total RNA was prepared according
to manufacturer's instructions. RNA integrity was assessed
by A260/A280 ratios (> 1.8 and < 2.1) and visualisation
of 18s and 28s ribosomal bands by electrophoresis with
formaldehyde denaturing 1% agarose gel.
Microarray procedure
The microarray procedure used in this study was essen-
tially as described in [14]. Briefly, Compugen Version 2 19
K oligonucleotide spotted glass microarrays (Clive and
Vera Ramaciotti Centre for Gene Function Analysis and
the Adelaide Microarray Facility, Australia) were used to
compare the amount of fluorescence (Cy3/Cy5) of each
matched pair on a single slide. Matched pairs were ana-
lysed in duplicate with a dye swap for the second microar-
ray to reduce the effects of dye incorporation bias. Indirect
labeling of the cDNA was performed using the CyScribe
Post-Labelling Kit (Amersham Biosciences, UK) as per
manufacturer's instructions. Briefly, total RNA (25 μg)
was reverse transcribed, using an oligo-dT primer, into
cDNA incorporating an amino-allyl modified d-UTP,
which was then labelled with either Cy5 or Cy3 fluores-
cent dyes and hybridised to the microarray for 16 h at 42-
C. Post-hybridisation, the microarrays were washed in
increasingly stringent solutions of SDS and SSC (1 × SSC
and 0.1% SDS at 50°C through to 0.1 × SSC at room tem-
perature) and then dried using centrifugation. Microar-
rays were scanned with the Axon GenePix 4000B
microarray scanner (Molecular Devices, California, USA),
the images were then analysed using the GenePix Pro 3.0
software. Areas of the microarray that were affected by
background were excluded from further analyses.
Microarray data analysis
GeneSpring 5.0 (Silicon genetics, USA) was used to nor-
malize per spot and per array (Lowess curve) and to a 50th
percentile. To determine the fold change corresponding to
a 5% error rate for this microarray platform a sample of
control human brain RNA was split in two and labelled
with Cy3 and Cy5 and hybridised in duplicate to a glass
microarray similar to those used throughout this study. To
identify significantly altered genes in the STG, one-class
significance analysis of microarrays (SAM) was performed
on Log 2 transformed expression data, with 128 permuta-
tions using SAM version 2.0 [33].
Relative real-time PCR
Relative real-time PCR was performed essentially as
described previously [32]. Briefly, 100 ng total RNA was
treated with DNAse 1 (Invitrogen, USA) and reverse tran-
scribed using oligo dT primers and Superscript II reverse
transcriptase (200U/μl) (Invitrogen, USA) as per manu-
facturer's instructions. Relative Real-time PCR using SYBR
green Mastermix (PE Applied Biosystems, UK) and an ABI
prism 7900 sequence detection system (PE Applied Bio-
systems, UK) was performed in triplicate to identify rela-
tive changed expression of IPLA2G, PIK31R1, Lin-7b and
ATBF1 compared to the housekeeping genes β-actin and
18s rRNA. The statistical significance of the altered expres-
sion was tested by a paired two-tailed t-test (p < 0.05), the
reported p values were calculated using the relative expres-
sion levels compared to 18s RNA. Bivariate correlation
analysis was performed to determine if there was any cor-
relation between the altered expression and the age, pH or
PMI. Correlation analysis could not be performed for
medication as many of the individuals with schizophrenia
had large ranges of reported dosage and the medication
history of one individual was unknown.BMC Genomics 2008, 9:199 http://www.biomedcentral.com/1471-2164/9/199
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